a longer-acting version of insulin glargine that made $300 million in the first quarter. The FDA approval was awarded to Mylan, which is now part of Viatris after merging with Pfizer's Upjohn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback